As we plan to bring our therapy-defining laboratory services into other specialties like oncology, we are excited to be collaborating with leading researchers in the field of Cancer Pain Management - Brian Meshkin, CEO, Proove Biosciences
Irvine, CA (PRWEB) April 24, 2014
Proove Biosciences, the leader in Personalized Pain Medicine testing services, will attend and exhibit research from current studies at the Third Annual Cancer Pain Conference hosted by The Valley Cancer Pain Foundation, a 501c3 nonprofit corporation dedicated solely to cancer pain research. The event will take place on April 25-27 in Scottsdale, Arizona.
Proove will again be the only company presenting data on how genetic analysis and testing can be utilized to improve the selection and dosing of pain medication. Proove Biosciences’ has been presenting how their proprietary research uses genetic analysis to predict the effectiveness, economic efficiency, and safety of patients suffering from pain.
Proove offers an evidence-based approach using therapy-defining laboratory tests to support best practices, like the Practice Guidelines for Cancer Pain Management from the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Proove testing can help a physician evaluate genetic factors that are part of complete medical history, psychosocial evaluation, diagnostic evaluations to ascertain or confirm the etiology of the pain, and treatment plan decisions.
The Annual Meeting is a dynamic educational opportunity that brings together pain and oncology physicians from across the United States to discuss the most up-to-date information on therapies available to treat cancer patients and pain. The event will bring together over 150 pain clinicians, anesthesiologists, neurosurgeons, and hospice providers from across the country. The event prides itself on dispersing the most recent information and data available on cancer pain treatments, with a focus on improving patient care, access to therapies, and overall outcomes.
The Third Annual Cancer Pain Conference is presented by Dr. Lisa Stearns and the Valley Cancer Pain Foundation. The goal is to present the most recent and relevant data and treatment options and provide a forum to interact and discuss evidence-based medicine and best practices to improve the access to and quality of care for patients.
“Proove Biosciences is excited to be participating in the Valley Cancer Pain Foundation’s Third Annual Conference, and to share and present our clinical data on how our Proove Genetic tests have been helping to improve clinical outcomes in pain medicine and reducing costs within our healthcare system,” stated Brian Meshkin, President of Proove Biosciences and author of the three studies. “As we plan to bring our therapy-defining laboratory services into other specialties like oncology, we are excited to be collaborating with leading researchers in the field of Cancer Pain Management.”
About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).